Lung Neoplasms  >>  Tecentriq (atezolizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
NCT01846416 / 2013-000177-69: A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Checkmark IASLC-WCLC 2015
Aug 2015 - Aug 2015: IASLC-WCLC 2015
Checkmark From FIR trial for advanced mNSCLC
May 2015 - May 2015: From FIR trial for advanced mNSCLC
Completed
2
138
US, Europe
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Genentech, Inc.
Non-Small Cell Lung Cancer
01/15
12/17

Download Options